14-day Premium Trial Subscription Try For FreeTry Free
$0.82
+0 (+0%)
At Close: Jul 27, 2023
Forecast Insider Trading Signals Historical Prices Predictions News Profile

IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference

 07:05am, Monday, 01'st Mar 2021
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference

IMV Reports Update on COVID-19 Vaccine Program

 07:05am, Monday, 28'th Dec 2020
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine

BTV Shines a Light on Companies to Invest In

 06:00am, Thursday, 10'th Dec 2020
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - On national TV Sat. Dec 12 & Sun. Dec 13, 2020 - BTV-Business Television spotlights the newest mining, cannabis, tech and pharmaceut

Durable Clinical Benefits Induced by IMV's T Cell Therapy in Combination With Merck's Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

 08:15am, Sunday, 06'th Dec 2020
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies

IMV's Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer

 07:10am, Thursday, 03'rd Dec 2020
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against i

IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy

 07:05am, Friday, 13'th Nov 2020
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious

IMV Inc. (IMV) CEO Frederic Ors on Q3 2020 Results - Earnings Call Transcript

 03:56pm, Thursday, 12'th Nov 2020
IMV Inc. (IMV) CEO Frederic Ors on Q3 2020 Results - Earnings Call Transcript

Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV's T Cell Therapy in Combination With Merck's Keytruda® in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting

 05:05pm, Wednesday, 04'th Nov 2020
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious

IMV (IMV) Investor Presentation - Slideshow

 01:44pm, Friday, 04'th Sep 2020
The following slide deck was published by IMV Inc. in conjunction with this event..

IMV INC (IMV) Reports Q2 Loss, Lags Revenue Estimates

 12:25pm, Wednesday, 12'th Aug 2020
IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

IMV Inc. Announces Second Quarter 2020 Financial Results

 11:05am, Wednesday, 12'th Aug 2020
IMV Inc. Announces Second Quarter 2020 Financial Results

Should You Buy IMV Ahead of Earnings?

 01:28pm, Tuesday, 11'th Aug 2020
IMV is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

IMV INC (IMV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

 04:30pm, Wednesday, 05'th Aug 2020
IMV INC (IMV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LD Micro - Announces Preliminary List of Presenters for the LD 500

 01:00pm, Wednesday, 05'th Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin

IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study

 11:05am, Wednesday, 05'th Aug 2020
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that Canadian
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE